Vertex Announces National Reimbursement Agreement in France for KAFTRIO® and SYMKEVI® for Eligible Cystic Fibrosis Patients

Vertex Pharmaceuticals Inc. announced a national reimbursement agreement with the French Health Authorities for the cystic fibrosis medicines KAFTRIO^® in a combination regimen with ivacaftor and SYMKEVIsup>® in combination with ivacaftor.